Sponsored by

Poster Number Index
Click on one of the following number ranges below to display a list of posters.
Click the checkbox next to each item to bookmark.

101 – 200 | 201 – 300 | 301 – 400 | 401 – 500 | 501 – 600 | 601 – 700 | 701 – 800
801 – 900 | 901 – 1000 | 1001 – 1100 | 1101 – 1200 | 2001 – 2100 | 2101 – 2200 | 3001 – 3100
3101 – 3200 | 4001 – 4100 | 4101 – 4200 | 5001 – 5100 | 5101 – 5200 | 6001 – 6100 | 6101 – 6152

  [1101] Sharing BRCA results: are there disparities?
  [1102] Enhanced mismatch mutation analysis: a new high throughput screening method for simultaneous detection of point mutation and gross gene rearrangement designed for BRCA1 and BRCA2 genes.
  [1103] Men attending a breast cancer risk evaluation clinic.
  [1104] Familial transmission of information dealing with BRCA1/2 mutations in hereditary breast and ovarian cancer.
  [1105] Characterization of estrogen receptor-positive breast cancers in BRCA1 mutation carriers.
  [1106] BRCA1 c.5181_5183delGTT (p.Val1688del) is a true pathogenic mutation that affects both protein stability and function: implications for genetic counseling.
  [1110] A potential role of EGFR-inhibitors for the prevention of BRCA1-related breast cancer.
  [1113] Expression profile of CYP19 in human breast cancer cell lines treated with indole-3-carbinol, 3,3'-diindolylmethane, and sulforaphane.
  [1115] Prospective evaluation of neurotoxicity in breast cancer patients treated with adjuvant paclitaxel.
  [1116] A case controlled, cross-sectional survey of joint and muscle aches, pains and stiffness in women with primary breast cancer.
  [1117] Impact of a home-based physical activity intervention upon exercise behaviors and anthropometric measures in women undergoing treatment for early stage breast cancer.
  [1118] Predictive markers of chemotherapy-induced menopause in premenopausal women under the age of 40 with breast cancer.
  [1119] Effect of airplane travel on women treated for breast cancer.
  [1120] Onset and risk factors for aromatase inhibitor-related arthralgia in breast cancer survivors.
  [1121] Wheel of Hope project: addressing disparities in complementary services for women with breast cancer in an underserved community.
  [1122] Utilization of internet-based survivorship care plans by breast cancer survivors.
  [1123] Baseline characteristics of women initiating follow-up care in a newly developed breast cancer survivorship center.
  [1124] Perception and measurement of strength and range of movement in women following treatment for breast cancer.
  [1125] Treatment of early breast cancer in women over 65: what is important? Retrospective trial.
  [1128] Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study.
  [1129] A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms.
  [1130] Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
  [1131] The effect of quantitative oestrogen receptor expression on recurrence in postmenopausal women with early stage breast cancer.
  [1132] A randomised study comparing the effects of anastrozole (A), letrozole (L), exemestane (E) and tamoxifen (T) on coagulation.
  [1133] Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the TEAM trial neuropsychological side study.
  [1134] NCIC CTG MA.17: hormone receptor expression of in-breast recurrences and contralateral primary breast cancers arising on aromatase inhibitors.
  [1135] Administrative claims: a novel approach in monitoring long term adherence to anti-hormonal therapy in breast cancer.
  [1136] Health-related quality-of-life and psychological distress of postmenopausal breast cancer patients after surgery during the randomized trial, N-SAS BC 03, comparing further tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1 to 4 years: the final results.
  [1137] Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE).
  [1138] Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
  [1140] Tolerance and consecutive patients adherence to hormonal treatment for early breast cancer.
  [1141] The decrease in grip strength in aromatase inhibitor-induced arthralgia is associated with extremes in body mass index and increased tenosynovial abnormalities.
  [1142] Effects of switching aromatase inhibitors on arthralgia: the ATOLL study.
  [1143] Bone effects of exemestane vs. tamoxifen within the TEAM trial: results of a prospective randomized bone sub study.
  [1144] A global perspective on the use of aromatase inhibitors in early-stage breast cancer.
  [1145] A randomised study of the effects of anastrozole (A), letrozole (L) and exemestane (E) on bone turnover.
  [1147] Vitreo-retinal traction and anastrozole use.
  [1148] Menopause surveillance recommendations for patients with endocrine responsive breast cancer.
  [1149] A synthetic PPARγ ligand sensitizes breast cancer cells to tamoxifen-induced apoptosis.
  [1150] Endocrine effects of adjuvant letrozole versus tamoxifen in hormone responsive postmenopausal early breast cancer patients: results from the HOBOE randomized trial.
  [1151] Adriamycin and cyclophosphamide followed by tamoxifen, versus the combination of gonadotropin-releasing hormone analog and tamoxifen, in the treatment of premenopausal endocrine-responsive node-negative breast cancer.
  [1152] A randomised study comparing the effects of anastrozole and letrozole on lipid metabolism.
  [1154] Effect of exemestane on bone turnover markers and bone mineral density (BMD): 2 year results of the Dutch/Belgian Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
  [1155] Effects of denosumab treatment in breast cancer patients with bone metastases and elevated bone resorption levels after therapy with intravenous bisphosphonates: results of a phase 2 randomized trial.
  [1156] Knockdown of c-Jun N-terminal kinase 1 expression in murine mammary cancer cells leads to an increase in tumor growth and bone metastasis.
  [1157] Suppression of bone resorption from odanacatib, a cathepsin K inhibitor, in women with bone metastases from breast cancer, and the effect of concomitant anti-neoplastic treatment on efficacy: a 4-week, double-blind, randomized controlled trial.
  [1159] Major issues in the treatment of metastatic bone disease: renal safety and maintained bone pain effectiveness of ibandronate in breast cancer patients in clinical practice; interim results of a non interventional study in Germany.
  [1160] ACE-011, a soluble activin receptor type IIA IgG-Fc fusion protein, decreases follicle stimulating hormone and increases bone-specific alkaline phosphatase, a marker of bone formation, in postmenopausal healthy women.
  [1161] HER-2/neu over-expressing DCIS phenotypes and the transition from in situ to invasive breast cancer: implications for breast cancer prevention.
  [1162] Local control with conventional and hypofractionated adjuvant radiotherapy for ductal carcinoma in-situ: is there a difference in outcome?
  [1163] The impact of preoperative magnetic resonance imaging on surgical planning for women with ductal carcinoma in situ.
  [1164] Evaluation of preoperative letrozole treatment to DCIS by MRMammography.
  [1165] Using mathematical models to understand the time dependence of the growth of ductal carcinoma in situ.

 
 

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved